Compare CENT & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENT | DYN |
|---|---|---|
| Founded | 1955 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.8B |
| IPO Year | 1996 | 2020 |
| Metric | CENT | DYN |
|---|---|---|
| Price | $45.01 | $16.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 17 |
| Target Price | ★ $53.00 | $35.73 |
| AVG Volume (30 Days) | 66.2K | ★ 2.8M |
| Earning Date | 11-23-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.41 | N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $3,129,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.22 | N/A |
| P/E Ratio | $15.90 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.22 | $14.00 |
| 52 Week High | $47.36 | $27.31 |
| Indicator | CENT | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 74.43 | 50.96 |
| Support Level | $42.52 | $16.55 |
| Resistance Level | $45.52 | $19.46 |
| Average True Range (ATR) | 1.30 | 0.89 |
| MACD | 0.52 | 0.35 |
| Stochastic Oscillator | 69.95 | 82.70 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.